Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Neurology

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000094376PMID 16825773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

  2005cited by this paper
• High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.

  2005cited by this paper
• Oxaliplatin-Associated Neuropathy: A Review

  2005cited by this paper
• Clinical management of oxaliplatin-associated neurotoxicity.

  2005cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Acute oxaliplatin-induced peripheral nerve hyperexcitability.

  2002cited by this paper
• Chemotherapy-induced peripheral neuropathy

  2002cited by this paper
• Oxaliplatin in practice.

  1998cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.

  1998cited by this paper
• Oxaliplatin (L-OHP): a new reality in colorectal cancer.

  1998cited by this paper
• Pharmacokinetics and safety profile of oxaliplatin.

  1998cited by this paper
• Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

  1997cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994cited by this paper
• Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity

  1992cited by this paper
• Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies.

  1982cited by this paper

• Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

  2025cites this paper
• Oxaliplatin reversibly and differentially affects electrogenic activity of small IB4(+) of male and female rat sensory neurons.

  2025cites this paper
• Possibilities of therapy for neuropathic pain caused by chemo-induced polyneuropathy

  2024cites this paper
• Albumin Nanoparticle Enhances Oxaliplatin Concentration in the Colorectal Region to Treat Colon Cancer with Increased Efficacy

  2024cites this paper
• Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial.

  2024cites this paper
• Oxaliplatin-induced Acute Neurotoxicity Recovers Between Repeat Infusion Cycles: An Axonal Excitability Repeated Multiple Measurements Study.

  2024cites this paper
• Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy.

  2024cites this paper
• Falls during oxaliplatin-based chemotherapy for gastrointestinal malignancies – (lessons learned from) a prospective study

  2023cites this paper
• The Predictors of Taxane Induce Peripheral Neuropathy as a Side Effect in Breast Cancer Patients among Iraqi Women

  2023cites this paper
• The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients

  2023cites this paper
• S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial

  2023cites this paper
• Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients

  2022cites this paper
• Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis

  2022cites this paper
• Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma

  2022cites this paper
• Therapeutic Efficacy of Traditional Chinese Medicine Syndrome-Based Formulae to Neuropathic Pain Caused by Chemotherapy

  2022cites this paper
• IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS

  2022cites this paper
• Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

  2022cites this paper
• Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

  2021cites this paper
• The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study

  2021cites this paper
• Approach to chemotherapy-induced peripheral neuropathy

  2021cites this paper
• α-Conotoxin RgIA and oligoarginine R8 in the mice model alleviate long-term oxaliplatin induced neuropathy.

  2021cites this paper
• Improved efficacy and safety of low-dose oxaliplatin/pegylated liposomal doxorubicin/S-1 regimen in advanced gastric cancer: a cohort study.

  2021cites this paper
• Neurotoxic Agents and Peripheral Neuropathy

  2021cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Clinical Assessment

  2021cites this paper
• Dorsal Root Ganglion Morphometric Changes Under Oxaliplatin Treatment

  2021cites this paper
• Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity

  2021cites this paper
• Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial.

  2020cites this paper
• Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents

  2020cites this paper
• Neurologic Complications

  2020cites this paper
• Long-Term Effects of Colorectal Carcinoma in Childhood and Adolescents

  2020cites this paper
• Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life

  2020cites this paper
• Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial

  2020cites this paper
• Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy‐induced polyneuropathy symptoms and signs

  2019cites this paper
• Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy‐induced peripheral neuropathy: A mediation effect analysis

  2019cites this paper
• Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cites this paper
• JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

  2019cites this paper
• Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

  2019cites this paper
• Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial—VANISH

  2019cites this paper
• The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP

  2018cites this paper
• The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

  2018cites this paper
• Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy—a randomized controlled pilot trial

  2018cites this paper
• Stratégie thérapeutique des neuropathies périphériques chimio-induites

  2018cites this paper
• [Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].

  2018cites this paper
• Détection précoce et quantification objective par mesures chronoampérometriques de l’atteinte neurologique périphérique chez des patients recevant une chimiothérapie neurotoxique

  2017cites this paper
• A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy

  2017cites this paper
• Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy

  2017cites this paper
• Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy

  2017cites this paper
• Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients

  2017cites this paper
• [Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy].

  2017cites this paper
• Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer.

  2017cites this paper
• Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.

  2016cites this paper
• Chemotherapy-induced peripheral neuropathy: an update on the current understanding

  2016cites this paper
• Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

  2016cites this paper
• Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

  2016cites this paper
• Late effects of oxaliplatin-induced peripheral neuropathy (LEON)—cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years

  2015cites this paper
• Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial

  2015cites this paper
• The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy.

  2015cites this paper
• Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity

  2015cites this paper
• Chemotherapy-induced Peripheral Neuropathy and Depression in Cancer Patients

  2015cites this paper
• Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

  2015cites this paper
• Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?

  2015cites this paper
• Exercise, concomitant to therapy, has a positive influence on therapy-induced side-effects in patients with haematological malignancies

  2014cites this paper
• Incidence of Cold-Induced Peripheral Neuropathy and Dose Modification of Adjuvant Oxaliplatin-Based Chemotherapy for Patients with Colorectal Cancer

  2014cites this paper
• Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study

  2014cites this paper
• Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects

  2014cites this paper
• Characterization of Acute and Chronic Neuropathies Induced by Oxaliplatin in Mice and Differential Effects of a Novel Mitochondria-targeted Antioxidant on the Neuropathies

  2014cites this paper
• Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study

  2014cites this paper
• Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

  2014cites this paper
• A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration

  2014influential citation
• Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors

  2013cites this paper
• Neuropatia Periférica em Pacientes com Câncer Colorretal em Tratamento com Oxaliplatina

  2013cites this paper
• Predicting Acute and Persistent Neuropathy Associated With Oxaliplatin

  2013cites this paper
• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

  2013cites this paper
• Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

  2013cites this paper
• Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy‐induced neuropathic pain resulting from peroxynitrite‐mediated post‐translational nitration of mitochondrial superoxide dismutase

  2013cites this paper
• Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.

  2012cites this paper
• Neuropatia induïda per Bortezomib. Caracterització i factors de risc en un model experimental

  2012cites this paper
• Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.

  2012cites this paper
• Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.

  2012influential citation
• Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

  2012cites this paper
• Predictors of Chemotherapy-Induced Peripheral Neuropathy

  2012cites this paper
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cites this paper
• Neurological complications of chemotherapy to the peripheral nervous system.

  2012cites this paper
• Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells.

  2012cites this paper
• Impact of oxaliplatin-induced neuropathy: a patient perspective

  2012cites this paper
• Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

  2012cites this paper
• The role of the organic cation/carnitine transporters in the uptake and neurotoxicity of oxaliplatin

  2012cites this paper
• Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?

  2011cites this paper
• PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.

  2011cites this paper
• Rôle du canal sodique Nav1.9 dans la douleur inflammatoire, dans la perception du froid et dans l'hypersensibilité au froid induite par l'oxaliplatine

  2011cites this paper
• Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?

  2011cites this paper
• Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool

  2011cites this paper
• Determination of oxaliplatin thermo-sensitive liposomes and its two main impurities

  2011cites this paper
• Colon cancer patients’incidence rate of peripheral neuropathy by treated with oxaliplatin and examing change of adverse effects by consultation

  2011cites this paper
• Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

  2011cites this paper
• Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

  2011cites this paper
• Combination therapy of metronomic S‐1 dosing with oxaliplatin‐containing polyethylene glycol‐coated liposome improves antitumor activity in a murine colorectal tumor model

  2010cites this paper
• Surviving Chemotherapy for Colon Cancer and Living with the Consequences

  2010cites this paper
• Chemotherapy-Induced Neurotoxicity

  2010cites this paper
• Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.

  2009cites this paper